Loss of NLRP3 disrupted this process, leading to heightened Th17 inflammatory output (IFN-γ, Granzyme B, TNF-α) and restored CD8+ T-cell cytotoxicity, ultimately constraining tumor growth [35]. The gene discussed is NLRP3; the disease is neoplasm.